Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effect of CYP2D6 genetic variation on patient-reported symptom improvement and side effects among children and adolescents treated with amphetamines.

Pharmacogenetics and genomics - 1 Jul 2024

Gerlach Samuel, Maruf Abdullah Al, Shaheen Sarker M, McCloud Ryden, Heintz Madison, McAusland Laina, Arnold Paul D, Bousman Chad A

Abstract excerpt

OBJECTIVES: Amphetamine-based medications are recommended as a first-line pharmacotherapy for the treatment of attention-deficit/hyperactivity disorder in children and adolescents. However, the efficacy and tolerability of these medications vary across individuals, which could be related to interindividual differences in amphetamine metabolism. This study examined if genotype-predicted phenotypes of the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adolescent
Share to Attention Deficit Disorder with Hyperactivity

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Central Nervous System Stimulants

Share to Cytochrome P-450 CYP2D6

Share to Genetic Variation

Share to Self Report

Share to Young Adult

Source

Identifiers

PMID: 38517706
DOI: 10.1097/FPC.0000000000000529

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effect of CYP2D6 genetic variation on patient-reported symptom improvement and side effects among children and adolescents treated with amphetamines.PMID 38517706Read ↗

Impact of Cytochrome P450 Genetic Variation on Patient-Reported Symptom Improvement and Side Effects Among Children and Adolescents Treated with Fluoxetine.Semantic proximity Read ↗

Clinical validity of cytochrome P450 metabolism and serotonin gene variants in psychiatric pharmacotherapySemantic proximity Read ↗

Atomoxetine pharmacogenetics: associations with pharmacokinetics, treatment response and tolerability.Semantic proximity Read ↗

Dopamine Transporter and CYP2D6 Gene Relationships with Attention-Deficit/Hyperactivity Disorder Treatment Response in the Methylphenidate and Atomoxetine Crossover Study.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium Guideline for <scp>Cytochrome P450 (<i>CYP</i>)</scp><i>2D6</i> Genotype and Atomoxetine TherapySemantic proximity Read ↗

MDMA, methamphetamine, and CYP2D6 pharmacogenetics: what is clinically relevant?Semantic proximity Read ↗

Polymorphisms in dopamine transporter (SLC6A3) are associated with stimulant effects of D-amphetamine: an exploratory pharmacogenetic study using healthy volunteers.Semantic proximity Read ↗

Dopamine transporter gene associated with diminished subjective response to amphetamine.Semantic proximity Read ↗

Effect of Individual and Combined Cytochrome P450 Activity Scores on Symptom Improvement and Side Effects in Youth Treated With Sertraline.Semantic proximity Read ↗

Evidence for Pharmacogenomic Effects on Risperidone Outcomes in Pediatrics.Semantic proximity Read ↗

Pharmacogenetic treatments for drug addiction: cocaine, amphetamine and methamphetamine.Semantic proximity Read ↗

CYP2D6 and clinical response to atomoxetine in children and adolescents with ADHD.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.